Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBX-MC-101
- Development stage
- Preclinical
- Lead developer
- Mybiotics Pharma
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
MBX-MC-101 is a live biotherapeutic product developed by MyBiotics Pharma. It is based on the company's MyCrobe technology, which enables the production and delivery of beneficial bacteria to restore and maintain healthy microbiota in the human body. Unlike traditional probiotics, this approach aims to overcome natural barriers to colonization and promote long-term microbiome restoration. MBX-MC-101 is being developed primarily for the treatment of antibiotic-associated diarrhea and vaginal flora imbalance (vaginal dysbiosis). The product is currently in preclinical development.
Beyond the preview
Go deeper on MBX-MC-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBX-MC-101.